Discover open access scientific publications

Randomized, Double-Blind, Placebo-Controlled Trial of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Asian Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin With or Without a Sulfonylurea (GetGoal-L-Asia)